Liraglutide · source year
5 selected, source-linked Liraglutide records carrying a 2014 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
5 selected records.
2 represented types.
5 distinct public records.
Cited chronology
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 206321 with status AP dated 2014-12-23, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01507389 at 2026-07-30T21:54:46.547Z. Its registry update date was 2014-12-09, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01270789 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2014-18304, attributed to FDA and its parent HHS department, on 2014-08-04. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01550653 at 2026-07-30T21:54:46.545Z. Its registry update date was 2014-02-27, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗